Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ibrutinib × Gastrointestinal × Clear all

Phase

Phase 1/2 3 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 100 Other hematologic neoplasm 50 Plasma cell 3 Myeloid 3 Thoracic 1 Head & Neck 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Classical hematology 1

Conditions

Gastrooesophageal Cancer 1

Interventions

Oxaliplatin 695 Fluorouracil 580 Capecitabine 504 Gemcitabine 426 Leucovorin 420 Irinotecan 402 Bevacizumab 397 Cisplatin 298 Radiotherapy 258 Cetuximab 224 S 1 (combination) 158 Paclitaxel 157 pembrolizumab 156 Docetaxel 144 Drug Therapy 127 Nivolumab 124 sintilimab 118 apatinib 118 tislelizumab 116 130-nm albumin-bound paclitaxel 111 durvalumab 109 Folfox protocol 105 Albumin-Bound Paclitaxel 99 Surgical Procedures, Operative 95 Panitumumab 95 camrelizumab 94 lenvatinib 93 Sorafenib 90 regorafenib 88 Radiation 81

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02884453 2019-09-18

iMYC

Royal Marsden NHS Foundation Trust

Phase 2 Unknown

Gastrointestinal

Gastrooesophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡